Sentry Acquires Emerge Tools to Help Developers Ship Better, Faster Mobile Apps
Sentry, the leading debugging platform for developers, today announced it has acquired Emerge Tools, a prominent provider of mobile app development solutions. Emerge Tools enables teams to deliver smaller, faster and more reliable mobile apps. Its platform powers visual regression testing at OpenAI and app size monitoring at Spotify. Companies like DoorDash have used Emerge to improve app launch speed by 60%, while Duolingo used Emerge to help delete thousands of lines of unnecessary code.
According to Statista, “mobile applications are projected to generate more than 613 billion dollars in revenue in 2025”. In a fast growing mobile app landscape, slow loading times, excessive battery drain, and UI instability can lead to negative user sentiment and app abandonment. Emerge Tools directly addresses these challenges by giving developers the ability to proactively identify and resolve performance bottlenecks, optimize app size, and maintain a consistent user experience.
“Emerge Tools is a leader in mobile development, with products used by some of the biggest apps in the world,” said Milin Desai, CEO of Sentry. “The rise of AI is reshaping how software is built and shipped and the need for quality tooling has never been greater, especially for mobile. Adding Emerge’s products and team will help Sentry continue to build the best possible platform for mobile developers around the world.”
Sentry, which is well known for error, crash reporting, and tracing tools will integrate Emerge Tools’s product line into their application monitoring platform – creating the most complete mobile app monitoring solution on the market. Companies like Anthropic, Instacart, Lyft, Riot Games, and more than 25,000 other organizations send Sentry over 4 billion mobile events a day. These Sentry customers will now be able to connect the inefficiencies surfaced by Emerge Tools down to the line of code causing lag, long load times, or unresponsive UI elements. All resulting in a smoother and more enjoyable app experience for users.
“We are thrilled to join Sentry and create a world-class mobile experience for developers,” said Josh Cohenzadeh, co-founder and CEO of Emerge Tools. “Together we will help mobile developers on their entire journey, all the way from their first lines of code to shipping to billions of users.”
“We’re especially excited about Sentry’s commitment to developers and Open Source. We look forward to further empowering the mobile community at an even larger scale,” said Noah Martin, co-founder of Emerge Tools. Sentry started the Open Source Pledge, an initiative that promotes Open Source sustainability and the direct funding of FOSS maintainers; Emerge Tools was one of the first companies to take the Pledge.
By leveraging Sentry and Emerge Tools, mobile development teams can:
- Significantly improve app performance and responsiveness.
- Reduce app size, resulting in higher install rates and user satisfaction.
- Enhance UI stability and prevent visual regressions.
- Streamline development workflows and reduce debugging time.
- Deliver superior mobile experiences that drive user engagement and retention.
This is the fourth major acquisition for Sentry, having acquired Specto in November 2021, Codecov in November 2022, and Syntax in April 2023.
Emerge Tools was founded in late 2020 by Josh Cohenzadeh & Noah Martin. They raised funding from Y Combinator, Haystack, Upside Partnership, Liquid 2 Ventures, and Matrix Partners.
About Sentry
Sentry helps every developer detect, understand, and fix broken code, fast. Using Sentry’s debugging platform decreases resolution time from days to minutes, giving developers more time to do the stuff they love, all while making customers happier. Sentry is used by over 4 million developers and 130,000 organizations, including Disney+, Cloudflare, GitHub, Anthropic, Vercel, and Atlassian.
About Emerge Tools
Emerge Tools provides performance and optimization tooling for mobile teams of all sizes. Its suite of products helps developers monitor and improve critical areas like app size, launch performance, visual regressions, and code health. Trusted by companies like OpenAI, Spotify, DoorDash, and Duolingo, Emerge empowers teams to ship high-quality apps.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506505021/en/
Contacts
MEDIA CONTACT
Michael Selvidge
media@sentry.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom